JINHAI MED TECH (02225) has been included in the Hang Seng Composite Index and is expected to become a target for the Stock Connect program.

On August 21, the Hang Seng Index Company announced the results of the quarterly review of the Hang Seng Index series as of June 30, 2026, in which JINHAI MED TECH (02225) was included in the Hang Seng Composite Index. The changes to the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect from September 7 (Monday), at which point the Shanghai and Shenzhen exchanges will accordingly adjust the scope of investable stocks under the Hong Kong Stock Connect. JINHAI MED TECH may be included in the Hong Kong Stock Connect as it meets a series of criteria including market capitalization and liquidity. On August 3, JINHAI MED TECH announced the appointment of Mr. Ma Chengdong as the Group's Chief Marketing Officer, effective from August 3, 2026, for an initial term of one year. According to the announcement, Ma Chengdong will be primarily responsible for the Group's marketing strategies, market access, academic promotion, and sales and channel operations, and will oversee the commercialization of the Group's medical devices and equipment products.